Clinical and laboratory values stratified by thrombotic events in patients with SCD
| . | n . | No thrombosis . | n . | Thrombosis . | P . |
|---|---|---|---|---|---|
| Age at first encounter, y | 985 | 23 (15-35) | 208 | 27 (21-39) | <.0001 |
| Male/female, % | 985 | 45/55 | 208 | 36/64 | .028 |
| African American, n (%) | 985 | 923 (94) | 208 | 200 (96) | .2 |
| Sickle cell genotype, % | 985 | 208 | <.0001 | ||
| HbSS/SB0 thalassemia | 66.7 | 83.7 | |||
| HbSC, SB+-thalassemia, or other | 33.3 | 16.3 | |||
| Hydroxyurea use, % | 985 | 496 (50) | 208 | 163 (78) | <.0001 |
| Tobacco use, % | 985 | 266 (27) | 208 | 87 (42%) | <.0001 |
| Body mass index, kg/m2 | 985 | 22 (18-26) | 208 | 23 (20-27) | .0031 |
| Systolic blood pressure, mm Hg | 985 | 115 (104-127) | 208 | 122 (110-132) | <.0001 |
| White blood cell count, ×103/μL | 985 | 9.7 (7.4-12.2) | 208 | 10.1 (7.6-12.5) | .13 |
| Platelet count, ×103/μL | 985 | 406.0 (287.0-525.0) | 208 | 402.5 (312.5-532.2) | .4 |
| Hb, g/dL | 985 | 9.6 (8.3-11.1) | 208 | 9.0 (8.2-10.2) | .002 |
| Hb F, % | 985 | 4.9 (2.1-11.2) | 208 | 4.7 (2.0-9.2) | .12 |
| Reticulocyte count, ×103/μL | 985 | 249 (158-384) | 208 | 291 (204-423) | .00012 |
| Lactate dehydrogenase, U/L | 985 | 289 (222-408) | 208 | 342 (247-443) | .018 |
| AST, U/L | 985 | 35 (25-47) | 208 | 38 (28-54) | .0016 |
| Serum creatinine, mg/dL | 985 | 0.7 (0.5-0.8) | 208 | 0.7 (0.6-0.9) | <.0001 |
| eGFR, mL/min/1.73 m2 | 985 | 146 (119-171) | 208 | 137 (101-154) | <.0001 |
| Hospitalizations, no. per year | 985 | 1 (0-3) | 208 | 3 (1-7) | <.0001 |
| Pregnancies, n (%) of patients | 545 | 105 (19) | 133 | 33 (25) | .15 |
| Orthopedic procedures, n (%) of patients | 985 | 29 (3) | 208 | 23 (11) | <.0001 |
| Central venous catheters, n (%) of patients | 985 | 244 (25) | 208 | 150 (72) | <.0001 |
| . | n . | No thrombosis . | n . | Thrombosis . | P . |
|---|---|---|---|---|---|
| Age at first encounter, y | 985 | 23 (15-35) | 208 | 27 (21-39) | <.0001 |
| Male/female, % | 985 | 45/55 | 208 | 36/64 | .028 |
| African American, n (%) | 985 | 923 (94) | 208 | 200 (96) | .2 |
| Sickle cell genotype, % | 985 | 208 | <.0001 | ||
| HbSS/SB0 thalassemia | 66.7 | 83.7 | |||
| HbSC, SB+-thalassemia, or other | 33.3 | 16.3 | |||
| Hydroxyurea use, % | 985 | 496 (50) | 208 | 163 (78) | <.0001 |
| Tobacco use, % | 985 | 266 (27) | 208 | 87 (42%) | <.0001 |
| Body mass index, kg/m2 | 985 | 22 (18-26) | 208 | 23 (20-27) | .0031 |
| Systolic blood pressure, mm Hg | 985 | 115 (104-127) | 208 | 122 (110-132) | <.0001 |
| White blood cell count, ×103/μL | 985 | 9.7 (7.4-12.2) | 208 | 10.1 (7.6-12.5) | .13 |
| Platelet count, ×103/μL | 985 | 406.0 (287.0-525.0) | 208 | 402.5 (312.5-532.2) | .4 |
| Hb, g/dL | 985 | 9.6 (8.3-11.1) | 208 | 9.0 (8.2-10.2) | .002 |
| Hb F, % | 985 | 4.9 (2.1-11.2) | 208 | 4.7 (2.0-9.2) | .12 |
| Reticulocyte count, ×103/μL | 985 | 249 (158-384) | 208 | 291 (204-423) | .00012 |
| Lactate dehydrogenase, U/L | 985 | 289 (222-408) | 208 | 342 (247-443) | .018 |
| AST, U/L | 985 | 35 (25-47) | 208 | 38 (28-54) | .0016 |
| Serum creatinine, mg/dL | 985 | 0.7 (0.5-0.8) | 208 | 0.7 (0.6-0.9) | <.0001 |
| eGFR, mL/min/1.73 m2 | 985 | 146 (119-171) | 208 | 137 (101-154) | <.0001 |
| Hospitalizations, no. per year | 985 | 1 (0-3) | 208 | 3 (1-7) | <.0001 |
| Pregnancies, n (%) of patients | 545 | 105 (19) | 133 | 33 (25) | .15 |
| Orthopedic procedures, n (%) of patients | 985 | 29 (3) | 208 | 23 (11) | <.0001 |
| Central venous catheters, n (%) of patients | 985 | 244 (25) | 208 | 150 (72) | <.0001 |
Values are median (IQR) unless otherwise noted.